Eisai to Use BioSeek's Drug Modeling Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asterand subsidiary BioSeek will collaborate on multiple oncology and inflammation-focused projects with the Japanese pharmaceutical company Eisai, Asterand said today.

Under the two-year agreement, the BioMap platform, which includes cell-based models designed to replicate interactions that are found in pharmacology and toxicology, will be used in research projects in both the US and Japan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.